CLOs on the Move

Patheous Health

www.patheous.health

 
Patheous Health is a company that specializes in dysphagia healthcare and swallowing impairment conditions. They offer an Integrated Dysphagia Healthcare (iDH) platform and provide service solutions for both MBS and FEES studies.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Spire Orthopedic

Spire Orthopedic Partners is a growing national partnership of orthopedic practices that provides the support, capital and operational resources physicians need to grow thriving practices for the future. As a management services organization, Spire provides the infrastructure for administrative operations that allows practices to operate at their highest level, so doctors can focus their efforts on what matters most – patient care. Rooted in the 100-plus-year legacy of its founding partners, the network spans the Northeast with 50 physicians, 450 employees and 10 locations from Connecticut to New York.

JPS Health Network

JPS Health Network is a $950 million, tax-supported health care system for Tarrant County in North Texas. Anchored by a 537-bed acute care hospital, the network includes more than 46 community-based clinics, including 20 school-based clinics. John Peter Smith Hospital is home to Tarrant County`s first and only Level 1 Trauma Center, its only psychiatric emergency services site and has the largest family medicine residency program in the nation. Our network employs more than 6,500+ people.

Cardiodyne

Cardiodyne is a Irvine, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Avaxia Biologics

Avaxia is a leader in the growing field of gut-targeted therapeutics — orally administered, minimally absorbed drugs that are designed to act locally in the gastrointestinal tract. Avaxia’s lead clinical candidate, AVX-470, is an oral anti-TNF antibody for inflammatory bowel disease. This transformative product offers potentially improved safety and efficacy over existing anti-TNF therapies by focusing immune suppression only where needed in the diseased gut. Avaxia plans to use its gut-targeted antibody platform to develop therapeutics to address many other serious diseases such as type 2 diabetes, celiac disease, GI acute radiation syndrome and oral mucositis.

MedPoint Digital

MedPoint is focused on innovative, high-value services. We are a global best-in-class company in our service areas. We work with clients on new approaches to training, education and communications that work in the real world of medicine.